Xenon Pharmaceuticals Inc. (XENE)
Xenon Pharma's epilepsy drug meets main goal in late-stage trial
Xenon Pharmaceuticals said on Monday its experimental epilepsy drug met the main goal of a late-stage trial, showing a statistically significant reduction in focal onset seizures.
Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus
XENE posts wider Q4 loss as R&D jumps 47%, but late-stage azetukalner studies and a $586M cash runway keep its pipeline in focus.
Xenon Pharmaceuticals Inc. (XENE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Xenon Pharmaceuticals Inc. (XENE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout
Xenon Pharmaceuticals (XENE) is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder treatment. XENE's $555M cash position supports operations into 2027, reducing near-term financing risk despite increased R&D and G&A expenses. Azetukalner's Phase 3 epilepsy and depression trials, strong long-term efficacy, and unique mechanism offer significant commercial upside.
Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation Transcript
Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation Transcript
Why Is Xenon Pharmaceuticals (XENE) Up 9.7% Since Last Earnings Report?
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock?
Polarean enters Asia with first Xenon MRI deal in Taiwan
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has secured its first foothold in Asia after National Taiwan University Hospital agreed to install one of the company's Xenon MRI research systems. The deal has been arranged through Philips, Polarean's long-standing strategic partner, and supported by Sumtage, the company's newly appointed distributor in Taiwan.
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
XENE reports narrower-than-expected Q3 loss as the biotech advances multiple late-stage studies of azetukalner across epilepsy and mood disorders.
Xenon Pharmaceuticals Inc. (XENE) Q3 2025 Earnings Call Transcript
Xenon Pharmaceuticals Inc. ( XENE ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Colleen Alabiso Ian Mortimer - President, CEO, Principal Accounting Officer & Director Christopher Kenney - Chief Medical Officer Thomas Kelly - Chief Financial Officer Darren Cline - Chief Commercial Officer and Member of Executive Team Conference Call Participants Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Tessa Romero - JPMorgan Chase & Co, Research Division Johoon Kim - RBC Capital Markets, Research Division Charles Moore - Robert W. Baird & Co. Incorporated, Research Division Dina Ramadane - BofA Securities, Research Division Joseph Thome - TD Cowen, Research Division Brian Balchin - Jefferies LLC, Research Division Presentation Operator Good day, everyone, and thank you for standing by.
Xenon Pharmaceuticals: Pushing Azetukalner Towards Finish Line With Phase 3 2026 Data Release
Xenon Pharmaceuticals is advancing azetukalner in multiple phase 3 trials for focal onset seizures, with topline X-TOLE2 data expected in early 2026. Azetukalner's mechanism and prior dose-dependent efficacy support its potential in epilepsy and neuropsychiatric indications, expanding its market opportunity. Xenon's strong cash position funds operations into 2027, with possible fundraising after key data readouts if results are positive.
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus
XENE's wider Q2 loss highlights its push toward late-stage epilepsy, depression, and bipolar disorder studies with azetukalner.
Xenon Pharmaceuticals Inc. (XENE) Q2 2025 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q2 2025 Earnings Conference Call August 11, 2025 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Christopher John Kenney - Chief Medical Officer Darren S. Cline - Chief Commercial Officer and Member of Executive Team Ian C.
